Clinical Trial Update: LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 study of the investigational agent LY3022855 in combination with BRAF/MEK inhibition for melano…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LY3022855

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-07-17